Dec. 18 at 4:58 PM
BioNTech (NASDAQ:
$BNTX) has closed its roughly
$1.25 billion all‑stock acquisition of CureVac, bringing in CureVac’s mRNA design, LNP delivery, and manufacturing assets to deepen BioNTech’s oncology‑focused mRNA platform, with 86.75% of CureVac shares already tendered and full squeeze‑out of the remainder expected in early 2026.
https://prismmarketview.com/biontech-completes-curevac-acquisition-expanding-its-mrna-platform/